Veeva Systems announced increasing adoption of Veeva Vault EDC as organizations – including 6 of the top 20 pharma – move to modernize clinical data management. Vault EDC’s data capabilities aim to streamline study build and data processing, to help save time, effort, and cost and provide a better research site experience.
 
With increasing trial complexity, biopharmaceutical companies look to agile systems that allow clinical teams to design, start, execute, and amend all types of studies quickly. Vault EDC provides dynamic design tools designed to automate manual processes and enable faster study builds. As the trial progresses, Vault EDC users can make amendments without data migrations.
 
“The industry is making significant progress in its move to patient-centric trials,” said Richard Young, vice president, Vault CDMS at Veeva. “We are committed to delivering the innovation data managers need to balance complex scientific efforts with the operational excellence that will advance clinical data management. Thanks to our customers, especially our early adopters, for partnering closely with us in the past few years as we have matured our product offerings.”
 
“Using Veeva Vault EDC’s innovative capabilities, we have seen a 30 to 35% improvement in study build timelines compared to what we did before 2021,” said Mayank Anand, vice president and global head of data strategy and management at GSK. “Veeva is a key part of our data strategy for the future.”